LENSAR (LNSR)
(Delayed Data from NSDQ)
$4.37 USD
-0.08 (-1.80%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $4.45 +0.08 (1.83%) 7:06 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.37 USD
-0.08 (-1.80%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $4.45 +0.08 (1.83%) 7:06 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
LENSAR, Inc. (LNSR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 23.86% and 4.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher Scientific (TMO) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 17.50% and 11.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: LENSAR, Inc. (LNSR) Q1 Earnings Expected to Decline
by Zacks Equity Research
LENSAR, Inc. (LNSR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.45% and 2.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in LENSAR, Inc. (LNSR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
LENSAR, Inc. (LNSR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LENSAR, Inc. (LNSR) Moves 13.5% Higher: Will This Strength Last?
by Zacks Equity Research
LENSAR, Inc. (LNSR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
LENSAR, Inc. (LNSR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 31.67% and 31.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Repro Med Systems, Inc. (KRMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 5.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Asensus Surgical (ASXC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 7.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Apollo Endosurgery, Inc. (APEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -35% and 0.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LENSAR, Inc. (LNSR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of -10.17% and 7.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will LENSAR, Inc. (LNSR) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
LENSAR, Inc. (LNSR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.